Behr TM - Search Results

1

99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.

von Guggenberg E, Behe M, Behr TM, Saurer M, Seppi T, Decristoforo C. von Guggenberg E, et al. Among authors: behr tm. Bioconjug Chem. 2004 Jul-Aug;15(4):864-71. doi: 10.1021/bc0300807. Bioconjug Chem. 2004. PMID: 15264875

2

Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.

Behr TM, Béhé MP. Behr TM, et al. Semin Nucl Med. 2002 Apr;32(2):97-109. doi: 10.1053/snuc.2002.31028. Semin Nucl Med. 2002. PMID: 11965605 Review.

3

Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.

Béhé M, Behr TM. Béhé M, et al. Among authors: behr tm. Biopolymers. 2002;66(6):399-418. doi: 10.1002/bip.10356. Biopolymers. 2002. PMID: 12658727

4

Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors.

Laverman P, Béhé M, Oyen WJ, Willems PH, Corstens FH, Behr TM, Boerman OC. Laverman P, et al. Among authors: behr tm. Bioconjug Chem. 2004 May-Jun;15(3):561-8. doi: 10.1021/bc034208w. Bioconjug Chem. 2004. PMID: 15149184

5

Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.

Béhé M, Becker W, Gotthardt M, Angerstein C, Behr TM. Béhé M, et al. Among authors: behr tm. Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1140-6. doi: 10.1007/s00259-003-1178-1. Epub 2003 May 24. Eur J Nucl Med Mol Imaging. 2003. PMID: 12768330 Clinical Trial.

6

Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin.

Behr TM, Jenner N, Radetzky S, Béhe M, Gratz S, Yücekent S, Raue F, Becker W. Behr TM, et al. Eur J Nucl Med. 1998 Apr;25(4):424-30. doi: 10.1007/s002590050241. Eur J Nucl Med. 1998. PMID: 9553173

7

Diagnostic applications of radiolabeled peptides in nuclear endocrinology.

Behr TM, Béhé M, Becker W. Behr TM, et al. Q J Nucl Med. 1999 Sep;43(3):268-80. Q J Nucl Med. 1999. PMID: 10568142 Review.

8

Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys.

Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Béhé M, et al. Among authors: behr tm. J Nucl Med. 2005 Jun;46(6):1012-5. J Nucl Med. 2005. PMID: 15937313 Free article.

9

Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.

Behr TM, Jenner N, Béhé M, Angerstein C, Gratz S, Raue F, Becker W. Behr TM, et al. J Nucl Med. 1999 Jun;40(6):1029-44. J Nucl Med. 1999. PMID: 10452322 Free article.

10

Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.

Behr TM, Béhé M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F, Becker W. Behr TM, et al. Clin Cancer Res. 1999 Oct;5(10 Suppl):3124s-3138s. Clin Cancer Res. 1999. PMID: 10541353

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters